Imunoterapia no tratamento do câncer
Immunotherapy in cancer treatment
Juliano José Jorge
Resumo
O avanço no conhecimento do funcionamento do sistema imunológico e de seu comportamento frente às neoplasias nos tem levado a novas modalidades de tratamento do câncer. Terapias como inibidores de checkpoint imunológico, transferência de células adotivas, anticorpos monoclonais e vacinas preventivas têm revolucionado o enfoque terapêutico para diversos tipos de neoplasias. Este documento traz uma breve descrição dos mecanismos de ação destas novas classes terapêuticas, com o objetivo de fornecer aos médicos alergistas e imunologistas noções de sua aplicação, ajudando-os e estimulando-os a aprofundar o conhecimento nas várias frentes de atuação no tratamento do câncer.
Palavras-chave
Abstract
Advances in the knowledge of how the immune system works and its behavior in relation to neoplasms have led to new modalities of cancer treatment. Therapies such as immunological checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies and preventive vaccines have revolutionized the therapeutic approach for various types of neoplasms. This paper provides a brief description of the mechanisms of action of these new therapeutic classes, with the aim of providing physicians and immunologists with notions of their application, helping and stimulating them to deepen the knowledge on the various fronts of action in cancer treatment.
Keywords
References
1. Sharma A, Campbell M, Yee C, Goswami S, Sharma P. Immunotherapy of cancer. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, eds. Clinical immunology: principles and practice. 5ª ed. Elsevier; 2018. p. 1033-48.
2. Nauts HC. Bacterial pyrogens: beneficial effects on cancer patients. Prog Clin Biol Res. 1982;107:687‑96.
3. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329‑60.
4. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):45‑65.
5. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56‑61.
6. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11(11):805‑12.
7. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909‑20.
8. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015;34(43):5411‑17.
9. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139‑48.
10. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084‑9.
11. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079‑84.
12. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62‑8.
13. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-Cells for cancer therapy. J Natl Cancer Inst. 2016;108(7):djv439.
14. Rooney C, Leen A. Moving successful virus-specific T-cell therapy for hematopoietic stem cell recipients to late phase clinical trials. Mol Ther Nucleic Acids. 2012;1(11):e55.
15. Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, et al. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res. 2015;21(3):534‑43.
16. Smaletz O, Mutti HB. Imunologia em Cancerologia. In: Geller M, Scheinberg MA, eds. Diagnóstico e Tratamento das Doenças Imunológicas. 2ª ed. Rio de Janeiro: Elsevier; 2015. p. 347-50.
17. Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, et al. Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treat Rev. 2010;36(Suppl 3):S1‑5.
18. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57‑66.
19. Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. Oncoimmunology. 2013;2(3):e23403.
Submitted date:
04/14/2019
Accepted date:
06/20/2019
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email